KOERS GALAPAGOS 2015

16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 251 252 253 254 255 256 257 258 259 260 261 ... 820 821 822 823 824 » | Laatste
egeltjemetstekel
0
Wat een ophef over koersontwikkeling,
Notabene in een weekend waarin er niet gehandeld word :-)
Maycon
0
Jammer dat er altijd bij dit soort ontwikkelingen er weer bashers om de hoek komen kijken....
DeZwarteRidder
0
quote:

Maycon schreef op 2 mei 2015 11:07:


Jammer dat er altijd bij dit soort ontwikkelingen er weer bashers om de hoek komen kijken....

Ja echt jammer...!!

En je zat net zo lekker op je roze wolk.....!!
pardon
0
Bristol-Myers' Supplemental BLA for Opdivo Accepted by FDA - Analyst Blog
Zacks By Zacks Equity Research
14 hours ago
????
Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. Regulatory updates include events like filing of marketing applications, acceptance of these applications for review by the regulatory agencies, reviews by advisory panels and, finally, a response from the regulatory agency regarding the approval status.

Earlier this week, Bristol-Myers Squibb Company BMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Opdivo for treatment-naive patients suffering from unresectable or metastatic melanoma.

In the sBLA, the company provided data on Opdivo compared to dacarbazine chemotherapy for previously untreated patients with BRAF wild-type advanced melanoma. The FDA also granted priority review status for this application. An action from the FDA is expected by Aug 27, 2015.

We note that Opdivo is already approved in the U.S. for the treatment of patients with unresectable or metastatic melanoma who are suffering from disease progression following treatment with Yervoy, and a BRAF inhibitor if they are BRAF V600 mutation positive. In Mar 2015, the drug also received approval in the U.S. for the treatment of patients with advanced squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.

Opdivo is one of the key products in Bristol-Myers’ portfolio and following its launch in Dec 2014 the drug generated revenues of $40 million in the first quarter of 2015. Label expansion efforts by the company for Opdivo are encouraging since we believe that widening the eligible patient population should open new channels of revenue generation.

Meanwhile, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended Opdivo’s approval for use in treatment-naive as well as treatment-experienced patients suffering from advanced unresectable or metastatic melanoma earlier in the month. This increases the likelihood of the candidate to receive approval from the European Commission (EC) since the EC takes the CHMP’s opinion into account while reviewing candidates.

Bristol-Myers carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Biogen Inc. BIIB, Actelion Ltd. ALIOF and Horizon Pharma plc HZNP. All these stocks carry a Zacks Rank #1 (Strong Buy).
SJURVM
0
There is a ew kondon the block Axa Investment Managers UK Ltd

investors.morningstar.com/ownership/s...

There will be some shuffling of stakes with some funds taking some or all of their profit i.e. BNP Paribas and then there will be new funds coming in to replace them.
That's part and parcel of investing.

THe SEC changes on 30.04 confirms that we are on course for a listing on Nasdaq. Shall we say the week of 18 May?


SJURVM
0
There is a new kid on the block Axa Investment Managers UK Ltd

investors.morningstar.com/ownership/s...

There will be some shuffling of stakes with some funds taking some or all of their profit i.e. BNP Paribas and then there will be new funds coming in to replace them.
That's part and parcel of investing.

THe SEC changes on 30.04 confirms that we are on course for a listing on Nasdaq. Shall we say the week of 18 May?
[verwijderd]
0
quote:

adje5 schreef op 2 mei 2015 09:30:


Het Galapagos verhaal MOET positief aflopen!

Galapagos heeft warrants gecreeerd voor werknemers

AMSTERDAM (Dow Jones)--Galapagos nv (GLPG.AE) heeft warrants gecreeerd en aangeboden aan werknemers en bestuurders, meldt het biotechbedrijf vrijdag.

In totaal zijn er 625.740 warrants gemaakt. Deze zijn hoofdzakelijk aan werknemers aangeboden en ook aan bestuurders.

De warrants hebben een uitoefentermijn van 8 jaar vanaf de datum van het aanbod en een uitoefenprijs van EUR28,75. Ze zijn niet overdraagbaar en krijgen geen notering.

Ieder warrant geeft het recht om in te schrijven op 1 nieuw aandeel Galapagos.

----------------------------- - See more at: beursig.nl/forum/viewtopic.php?f=4&am...

Dit zeg toch genoeg,op naar het goud.Eind dit jaar rond de 100 als ze nog genoteerd staan.

Fijn weekend ieder


Over 8 jaar pas uit te oefenen dus na 1 mei 2023.
Hopelijk blijft Galapagos ook zelfstandig tot in 2023 en maken wij dat ook mee als aandeelhouders van Galapagos.




SJURVM
0
Abbvie is not having it easy to buy Pharmacyclics. THe offer has been extended again.
NORTH CHICAGO, Ill., May 1, 2015 /PRNewswire/ -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 15, 2015.

The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 1, 2015, a total of approximately 51,470,840 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer.
[verwijderd]
0
quote:

SJURVM schreef op 1 mei 2015 21:48:


Yes that is part of the "risk factors" one has to put in a prospectus.

I think this has been discussed at length on this forum as to why Abbvie would do such a thing. Unless their own was as good as filgotinib.
On the balance of probabilities Abbvie is in more need to replace Humira with another blockbuster than not do the right commercial thing.

Financially a take-over is cheaper (and they would get the other programs too).

But yes if the so wished for whatever reason to could leave the grapes to dry out on the vine as it were.


You will understand that I am quite against anyone who wants grapes to dry out on the vine. Nurturing the grapes and the vines is much better and the grapes need to be harvested every year at the right time.

I expect that Onno has taken good note of the developments at Crucell with the Sanofi flu project and that he has inserted sufficient contractual stipulations in the contract with ABBVIE to avoid such from happening with 634.

Also the situation is now quite different as the production process of 634 is not that a dramatic shift (triggering write offs) as it would have been for Sanofi to move from flu production in eggs to cell culture.
Also 634 promises to wipe out biosimilar (TNF) competition currently threatening Humira.


SJURVM
0
quote:

grapesharvester schreef op 2 mei 2015 12:25:


[...]

You will understand that I am quite against anyone who wants grapes to dry out on the vine. Nurturing the grapes and the vines is much better and the grapes need to be harvested every year at the right time.

I expect that Onno has taken good note of the developments at Crucell with the Sanofi flu project and that he has inserted sufficient contractual stipulations in the contract with ABBVIE to avoid such from happening with 634.

Also the situation is now quite different as the production process of 634 is not that a dramatic shift (triggering write offs) as it would have been for Sanofi to move from flu production in eggs to cell culture.
Also 634 promises to wipe out biosimilar (TNF) competition currently threatening Humira.


Yes I much prefer to harvest the grapes and drinking the good wine made from them.
I can't indeed believe that Abbvie would go down that route as it would make no commercial sense whatsoever.
I know some people are concerned that Abbvie's own drug might be as good as 0634 but again on this forum it has been discussed Harrysnel? aston.martin? that it is not quite the real McCoy.

The real question is what is the cheapest option for Abbvie?

Considering the difficulties they are having in acquiring Pharmacyclics where not all shareholders have tendered their shares ( are they waiting for a higher offer?) it might not go for a take-over after all. But then those payments and royalities....

We shall wait and see.

Next step is Nasdaq. Wider institutional ownership. Money raised will serve to replace the cash burn this year and next.

Who knows, if still independent, a new issue will be raised in 2016 but in Europe this time with the likes of KBC & UBS etc to keep them sweet? THis to pay for the development of the drugs in the pipeline.

One way or another the price will move upwards with time.





Roan3009
4
De afgelopen dagen de berichten op het forum eens allemaal goed doorgelezen! Begrijp eigenlijk niet zo goed dat veel nieuwkomers bij Galapagos zo door het dolle heen zijn bij een koers van > 37? Waarom niet een paar jaar geleden ingestapt op 10, 15 of 18 euro ? Het mooie bedrijf Galapagos is in feite niet echt veel veranderd! De passie en hartstocht van de CEO is niet veranderd! Blijkbaar geloofde velen daar niet echt in! Gelukszoekers zijn nu ervaringsdeskundigen geworden, en ervaringsdeskundigen verdwijnen door het stijgende tokkie gehalte van het forum naar de achtergrond! Een jammerlijk verschijnsel!!!
egeltjemetstekel
1
Daar kan ik mij heel goed in vinden roan!
Maar dat is nu eenmaal zoals het gaat...
En daarom ook niet onverwacht! en bovendien doe je er niks aan.
En trouwens, ik vind dat er ook posters bijgekomen zijn die juist wel een goede bijdrage leveren!
durobinet
0
Een pluim en een tien met een griffel van mij Roan!
Hoop dat je niet teveel op de achtergrond verdwijnt!
SJURVM
0
In terms of the warrants issued yesterday

The warrants are not transferable and can in "principle" not be exercised prior to the end of the "third calendar year" after the year in which they were granted to the beneficiaries
.
E.v.B
0
Voordat we verder kijken naar de lange termijn. Wat denken jullie dat de koers gaat doen DEZE week?
16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 251 252 253 254 255 256 257 258 259 260 261 ... 820 821 822 823 824 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 16 jun 2021 17:36
Koers 63,690
Verschil -0,240 (-0,38%)
Hoog 64,330
Laag 62,920
Volume 250.188
Volume gemiddeld 495.331
Volume gisteren 198.253